



# *In Vitro* Determination of Hydrolytic Enzymes and Echinocandin Susceptibility in Mexican Clinical Isolates of *Candida glabrata* Sensu Stricto

Rogelio de J. Treviño-Rangel<sup>1</sup>, José F. Espinosa-Pérez<sup>1</sup>, Hiram Villanueva-Lozano<sup>1</sup>, Laura A. Soto-Quintana<sup>1</sup>, Alexandra M. Montoya<sup>1</sup>, Carolina E. Luna-Rodríguez<sup>1</sup> and Gloria M. González<sup>1,\*</sup>

<sup>1</sup>Department of Microbiology, Faculty of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico

\*Corresponding author: Department of Microbiology, Faculty of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico. Email: gmglez@yahoo.com.mx

Received 2018 October 08; Revised 2019 May 17; Accepted 2019 May 19.

## Abstract

**Background:** *Candida glabrata* is an opportunistic yeast that has emerged as a cause of human fungal disease, and is a complex of three closely related species. Until now, there is not enough information about its virulence attributes. Moreover, its resistance to echinocandins has been documented, which is a cause of clinical concern.

**Objectives:** The objective of this study was to evaluate the *in vitro* production of aspartyl proteinase, phospholipase, esterase, hemolysin, DNase, and coagulase in a subset of 107 Mexican clinical isolates of *C. glabrata* sensu stricto, as well as to determine its echinocandin susceptibility.

**Methods:** The enzymatic determinations were carried out in plate assays using specific substrates, excepting coagulase, which was determined by the classic tube test. Antifungal susceptibility testing was determined in accordance with the CLSI broth microdilution method.

**Results:** Aspartyl proteinase, hemolysin, and phospholipase were detected in 100%, 95%, and 79% of isolates, respectively. Blood isolates were associated with a very strong activity of aspartyl proteinase and hemolysin, and those recovered from vaginal swabs were associated with very strong production of aspartyl proteinase, phospholipase, and hemolysin. All isolates were susceptible to echinocandins, except one bloodstream isolate, which was resistant to echinocandins.

**Conclusions:** A very strong activity of aspartyl proteinase and hemolysin was particularly associated with both, bloodstream, and vaginal swab isolates. Echinocandin resistance was rare.

**Keywords:** *Candida glabrata*, Phospholipases, Aspartyl Proteinases, Esterases, Hemolysins, Echinocandins

## 1. Background

*Candida glabrata* is an emerging human fungal pathogen, ranking as the second or third common cause of clinical forms of candidosis (1-3), highlighting bloodstream infections due to its unacceptable high mortality rate ranging from 58% to 61% (4). Furthermore, *C. glabrata* is a species complex comprised of *C. glabrata* sensu stricto, *C. nivariensis*, and *C. braccarensis* (5, 6). On the other hand, the adherence to host tissues, rapid response to changes in the microenvironment, and the ability to secrete hydrolytic enzymes are all considered virulence attributes that enable *Candida* species to cause disseminated infections in susceptible hosts (7). Particularly, hydrolytic enzymes have been exhaustively studied in *C. albicans*, yet there is limited information with respect to non-*albicans*

*Candida* species, such as *C. glabrata*.

Treatment of *C. glabrata* infections represents an authentic challenge due to the scarce knowledge of *C. glabrata* pathogenicity, the increased probability of the organism to develop resistance to azole derivatives, as well as a limited antifungal repertoire (8). The reduced susceptibility of *C. glabrata* to fluconazole has increased the clinical value of echinocandins, leading ESCMID and IDSA to propose them as the first-line therapy against this yeast (9). However, resistance to echinocandins has also emerged, alarmingly increasing the number of case reports of *C. glabrata* resistant isolates following echinocandin therapy (10). Thus, local and global antifungal susceptibility surveillance of this threatening pathogen becomes critical in order to document epidemiological shifts and trends. Overall, the aim of this study was to assess the production

of lytic enzymes, such as aspartyl proteinase (AP), phospholipase (PP), esterase (ES), hemolysin (HM), DNase (DA), and coagulase (CO) in a subset of *C. glabrata* sensu stricto clinical isolates, as well as to determine its antifungal susceptibility to echinocandins.

## 2. Objectives

The present study evaluated the production of some hydrolytic enzymes in a subset of 107 Mexican clinical isolates of *C. glabrata* sensu stricto. Moreover, its antifungal susceptibility to caspofungin, anidulafungin, and micafungin was determined.

## 3. Methods

### 3.1. Isolates

One hundred and seven isolates of *C. glabrata* were recollected between 2005 to 2015 at the Department of Microbiology, UANL in Mexico. These isolates were collected from different patient samples and incubated at 37°C on Sabouraud Dextrose Agar (SDA) (Difco, USA) for 24 hours. Isolates were identified as *C. glabrata* employing API-20C-AUX strips (bioMérieux, Mexico). In order to confirm the identity of the isolates, DNA extraction by the organic (phenol-chloroform) method was performed (11) and the non-coding ITS region of the rDNA was amplified in a T100 Thermal Cycler (BIO-RAD; Hercules, USA), using the primers IT5 (5'-GGAAGTAAAAGTCGTAACAAGG-3') and ITS4 (5'-TCCTCCGCTTATTGATATGC-3') (12). Once amplicons were purified (Promega; Madison, USA), they were sequenced by Sanger and the obtained sequences were then compared by BLAST with sequence deposits available from the NCBI/GenBank and ISHAM ITS databases. The samples from which the isolates were collected were as follows: 43 (40.2%) from blood, 28 (26.2%) from vaginal swab of Vulvovaginal Candidiasis (VVC) cases, 23 (21.5%) from urine, and 13 (12.1%) from diverse sites, such as peritoneal fluid (8), intra-abdominal abscess (2), cerebrospinal fluid (1), hepatic cyst (1), and bronchial secretion (1). All isolates were preserved on agar slants at -20°C.

### 3.2. Enzymatic Activity Assays

The activity of AP, PP, ES, and HM were quantitatively assessed using plate assays with specific test media, such as YCB-BSA medium (Difco & Bio Basic, USA) (13), egg-yolk agar (Difco, USA) (14), tween 80 opacity test medium (Difco & Sigma-Aldrich, USA) (15), and SDA (Difco, USA) with 7% blood (16), respectively. Five microliters of a 10<sup>7</sup> CFU/mL adjusted suspension was inoculated in specific media, while

10 µL was spotted for the hemolytic assay. Plates were incubated for two, five, seven, and ten days at 37°C for the determination of HM, PP, AP, and ES, respectively. Enzymatic activities were evaluated using the Pz index and the classification criteria were as follows: very strong, Pz < 0.69; strong, Pz = 0.70 - 0.79; mild, Pz = 0.80 - 0.89; weak, Pz = 0.90 to 0.99; and negative, Pz = 1 (17).

Additionally, DA and CO activities were qualitatively determined employing a medium with methylene green (Difco, USA) and a commercial rabbit plasma (Difco, USA), respectively (18). Both determinations were conducted according to the manufacture's recommendations.

All assays were done in duplicates. The quality controls used for AP, PP, ES, and HM determinations were *C. albicans* ATCC 90028 and *C. tropicalis* ATCC 750, while *Staphylococcus aureus* ATCC 29213 was utilized for DA and CO assays. Complementarily, in order to compare the results with other published studies, a comprehensive literature review was performed using the platform PubMed of the National Center for Biotechnology Information ([www.ncbi.nlm.nih.gov/pubmed/](http://www.ncbi.nlm.nih.gov/pubmed/)) under the criteria of search: '*Candida glabrata* hydrolytic enzymes'.

### 3.3. Antifungal Susceptibility Testing

The antifungal susceptibilities of the isolates to the echinocandins caspofungin, anidulafungin, and micafungin were in accordance with the most recent approved broth microdilution method of CLSI, M27-A4 protocol (19). In brief, two-fold serial dilutions were prepared for each antifungal, and further dilutions were made in RPMI 1640 with MOPS (Hardy Diagnostics, USA). The drug's working concentrations were 0.015 to 8 µg/mL. Plates were incubated at 35°C and then read after 24 hours of incubation. Furthermore, *C. krusei* ATCC 6258 and *C. parapsilosis* ATCC 22019 were used as quality control organisms. The MIC breakpoints for the interpretation of results were those established by CLSI. Isolates with MICs of ≤ 0.12 µg/mL for anidulafungin and caspofungin and of ≤ 0.06 µg/mL for micafungin were considered susceptible; in counterpart, isolates with MICs of ≥ 0.5 µg/mL for anidulafungin and caspofungin and of ≥ 0.25 µg/mL for micafungin were considered resistant.

### 3.4. Statistics

The enzymatic profiles of the isolates were correlated based on their clinical origin with chi-square and Fisher's tests using SPSS version 17.0 for Windows (SPSS; Chicago, USA). P values ≤ 0.05 were considered significant.

## 4. Results

All analyzed isolates were identified as *C. glabrata* sensu stricto, according to the sequence analysis of the ITS inter-

genic region; sequences are available in GenBank (accession numbers: MF187218 to MF187325).

The enzymatic profiles of the *C. glabrata* sensu stricto isolates evaluated in this study are summarized in Table 1. The AP was secreted by all strains with a very strong activity, excepting for two bloodstream isolates and one strain from vaginal swab. On the other hand, 84 isolates (78.5%) were PP producers with different activity levels, highlighting the finding that all vaginal isolates were very good producers of this enzyme. In counterpart, ES was expressed only by 13 isolates (12.1%), none from urine. Regarding HM, 102 isolates (95%) were hemolytic, exhibiting a very strong activity, especially among isolates recovered from blood, vaginal swab, and diverse other origins. The DA and CO were all negative for the subset of isolates studied. The bloodstream isolates were statistically associated with a very strong activity of AP and HM ( $P < 0.001$ ), while the vaginal specimens were particularly associated with a very strong production of AP and PP ( $P < 0.001$ ), as well as HM ( $P = 0.022$ ). Moreover, the literature review is presented in Table 2, and includes 14 reports; AP and PP were the enzymes more extensively examined.

Regarding the antifungal susceptibilities of the isolates, the MIC<sub>90</sub> for the three drugs was 0.0625 µg/mL with ranges of 0.0156 to 1 µg/mL for anidulafungin, 0.03125 to 0.5 µg/mL for caspofungin, and 0.03125 to 0.25 µg/mL for micafungin. A very low incidence of echinocandin resistance was detected with only one bloodstream isolate resistant to the three echinocandins, exhibiting a MIC of 1 µg/mL for anidulafungin and caspofungin, and a MIC of 0.5 µg/mL for micafungin.

## 5. Discussion

The pathogenicity of *Candida* spp. is determined by the expression of several virulence attributes, such as adherence to host cells, phenotypic switching, the ability to form biofilms, and the capability to produce and secrete hydrolytic enzymes (34, 35). These play a major role in adherence, penetration, invasion, and destruction of host tissue (35), contributing significantly to the pathogenicity of *Candida*. Some of the most commonly described extracellular hydrolases are AP, lipolytic enzymes, and HM. Importantly, production of these enzymes varies between species and also depends on the source or site of infection (36). In this sense, for example, the current study found an association between *C. glabrata* sensu stricto isolates from vaginal swabs with a very strong production of AP, PP and H; findings also reported on a strain of *C. braccarensis* isolated from the same site of infection in a Mexican woman with VVC (18).

Aspartyl proteinase enables *Candida* invasion and tissue colonization by disruption of host membranes, while

**Table 1.** Enzymatic Activities of the Clinical Isolates Studied in This Work

Enzyme Evaluated	Origin (N)			
	Blood (43)	Urine (23)	Vaginal Swab (28)	Others (13)
<b>Aspartyl proteinase</b>				
Very strong	41	23	27	13
Strong	1	0	1	0
Mild	1	0	0	0
Weak	0	0	0	0
Negative	0	0	0	0
<b>Phospholipase</b>				
Very strong	18	8	27	5
Strong	2	11	1	0
Mild	3	2	0	5
Weak	0	0	0	2
Negative	20	2	0	1
<b>Esterase</b>				
Very strong	5	0	5	3
Strong	0	0	0	0
Mild	0	0	0	0
Weak	0	0	0	0
Negative	38	23	23	10
<b>Hemolysin</b>				
Very strong	38	11	27	12
Strong	2	4	0	0
Mild	0	6	0	0
Weak	0	2	0	0
Negative	3	0	1	1

controls several steps in innate immune evasion degrading structural and immunological defense proteins (34). In the present study, the researchers found that all strains showed proteolytic activity, with an elevated percentage of isolates with very strong activity of AP (97.2%). As depicted in Table 2, Figueiredo-Carvalho et al. (33) recently reported similar findings in a collection of 91 strains of *C. glabrata* from diverse clinical sources. However, in the literature, there are several reports with lower variable incidence of proteolytic activity (24, 26, 28, 29, 31) and some authors did not detect such enzymatic activity, probably due to the very limited number of *C. glabrata* strains they tested (21, 30, 32). On the other hand, PP and ES are extracellular lipolytic enzymes that contributed to the virulence of *Can-*

Table 2. Comprehensive Literature Review

Reference	Country	No. <i>C. glabrata</i> Isolates (Clinical Origin)	Method (s) of Identification	Enzymatic Activities: No. Isolates with Activity (%)					
				AP	PP	ES	HM	CO	DA
Aktas et al. (20)	Turkey	12 (NS)	API 20C AUX	-	-	0 (0)	-	-	-
Kantarcioğlu and Yücel (21)	Turkey	4 (NS)	Fermentation and assimilation tests	0 (0)	1 (25)	-	-	-	-
Rodrigues et al. (22)	Portugal	25 (NS)	API ID 32C	-	-	-	-	5 (20)	-
Gökçe et al. (23)	Turkey	6 (blood)	API ID32C	ND	0 (0)	-	-	-	-
Oksuz et al. (24)	Turkey	9 (RS = 3, GU = 1, OM = 1, fecal = 1, skin = 3)	API ID 32C	1 (11.1)	0 (0)	-	-	-	-
Yigit et al. (25)	Turkey	14 (NS)	API 32C AUX	-	-	-	-	6 (42.8)	-
D'Eca Junior et al. (26)	Brazil	10 (urine = 7, TS = 3)	Vitek	6 (60)	7 (70)	-	-	-	-
Chin et al. (27)	Malaysia	4 (NS)	CHROM agar <i>Candida</i> /ITS sequencing	-	0 (0)	-	4 (100)	-	-
Tellapragada et al. (28)	India	13 (VS = 11, blood = 2)	HiChrome <i>Candida</i> agar/Vitek 2/PCR multiplex (ITS)	2 (15.3)	0 (0)	0 (0)	-	-	-
Deorukhkar et al. (29)	India	93 (VS = 41, urine = 24, OM = 11, blood = 8, CSF = 4, miscellaneous = 5)	Assimilation tests/HiChrome <i>Candida</i> agar	56 (60.2)	61 (65.5)	-	62 (66.6)	45 (48.3)	-
Mutlu Sarıgüzel et al. (30)	Turkey	2 (blood)	API 20C AUX/ITS sequencing	0 (0)	0 (0)	0 (0)	-	-	-
Atalay et al. (31)	Turkey	14 (blood)	CHROM agar <i>Candida</i> /API 20C AUX	4 (28.5)	5 (35.7)	1 (7.1)	-	-	-
Riceto et al. (32)	Brazil	5 (NS)	ND	0 (0)	0 (0)	-	5 (100)	-	0 (0)
Figueiredo-Carvalho et al. (33)	Brazil	91 (blood = 25, urine = 13, RS = 10, feces = 9, VS = 7, miscellaneous = 27)	API 20C AUX/CHROM agar <i>Candida</i> /Vitek 2/ITS sequencing	87 (95.6)	0 (0)	51 (56)	90 (98.9)	-	-
<b>This study</b>	Mexico	107 (blood = 43, VS = 28, urine = 23, miscellaneous = 13)	API 20C AUX/ITS sequencing	107 (100)	84 (78.5)	13 (12.1)	102 (95.3)	0 (0)	0 (0)

Abbreviations: AP, aspartyl proteinase; CO, coagulase; CSF, cerebrospinal fluid; DA, DNase; ES, esterase; GU, genitourinary tract; HM, hemolysin; ITS, internal transcribed spacer region; ND, not defined; NS, not stated; OM, oral mucosa; PCR, polymerase chain reaction; PP, phospholipase; RS, respiratory samples; VS, vaginal swab.

*dida* spp., possibly through damage to the host cell membrane by digestion of lipids, facilitating tissue invasion as well as nutrient acquisition (35)

In this work, the researchers detected 84 isolates (78.5%) with PP activity at different production levels, with these observations agreeing closely with certain studies (26, 29) and more distantly with some additional reports (21, 31); as opposed, other authors did not find PP activity (23, 24, 27, 28, 30, 32), even in collections of numerous strains of *C. glabrata* (33). Otherwise, as expected, a limited number of isolates (12.1%) exhibited ES activity, agreeing with some studies (20, 28, 30, 31) and in contrast to the work of Figueiredo-Carvalho et al. (33), who reported an incidence of 56%, and further suggested that the production of this enzyme may vary according to the clinical source or the geographic region, from which the strains were iso-

lated.

Hemolysin is important for elemental iron uptake from hemoglobin through lysis of red blood cells. Thus, this putative virulence factor enables pathogen survival and persistence in the host (37). In the present study only five isolates were unable to produce HM, these findings are in agreement with previous publications (27, 32, 33), reflecting the importance of this key virulence attribute for *C. glabrata*. In fact, the hemolytic activity has been demonstrated as necessary for virulence in this yeast (38). On the other hand, although less studied, other extracellular lytic enzymes that also contribute to the pathogenic fitness of *Candida* spp. are CO and DA. In this study, these enzymes were not produced among the studied isolates, in contrast with scarce works (22, 25, 29) and in agreement with the findings communicated by Riceto et al. (32).

Echinocandins are the front-line antifungals for the treatment of candidemia and other forms of invasive candidiasis due to *C. glabrata* (9). Although case reports were initially infrequent, echinocandin resistance in *Candida* spp. is emerging, particularly in *C. glabrata*. This phenomenon mostly occurs in patients with long periods of echinocandin treatment or prophylaxis, and it is principally related to mutations in hot-spot regions of *FKS* gene, which participate in the production of 1,3- $\beta$ -D-glucan synthase (39), manifesting phenotypically with magnitudes of change in the MIC values.

In the present study, echinocandins exhibited excellent *in vitro* activity against the studied isolates, with only one strain (0.9%) resistant to the three candins tested. Similar results were previously reported by Morales-Lopez et al. (40) in an Argentinian collection of 114 clinical strains of *C. glabrata sensu stricto*. Even though the incidence of echinocandin-resistant isolates of *C. glabrata* is low at the moment, it seems to be on the rise, and the available information is fragmentary, coming from single case reports or series with limited number of patients. The conduction of surveillance studies such as the current research is essential in order to monitor antifungal resistance and to announce the regional epidemiology of *C. glabrata sensu stricto*.

### 5.1. Conclusions

The bloodstream isolates of *C. glabrata sensu stricto* were associated with a very strong activity of AP and HM, while those recovered from vaginal swabs were particularly associated with a very strong production of AP, PP and HM. On the other hand, echinocandin resistance was rare in the subset of isolates evaluated.

### Footnotes

**Authors' Contribution:** Rogelio de J. Treviño-Rangel, José F. Espinosa-Pérez and Gloria M. González contributed to study concept and design, drafted the manuscript, and analyzed and interpreted the data. Hiram Villanueva-Lozano and Alexandra M. Montoya made substantial contributions to conception and experimental design. José F. Espinosa-Pérez and Laura A. Soto-Quintana performed the experiments. Carolina E. Luna-Rodríguez helped with laboratory examinations. Hiram Villanueva-Lozano and Alexandra M. Montoya participated in the data analysis. All authors read and approved the final manuscript.

**Conflict of Interests:** It is not declared by the authors.

**Ethical Approval:** This study was registered and approved by the Research Ethics Committee of School of Medicine, Universidad Autónoma de Nuevo León with registration number: MB15-001

([http://www.medicina.uanl.mx/investigacion/sometimiento\\_protocolo/](http://www.medicina.uanl.mx/investigacion/sometimiento_protocolo/)).

**Financial Disclosure:** The authors declare that they had no financial interests related to the material in the manuscript.

**Funding/Support:** This study was supported by internal resources of Departamento de Microbiología, Facultad de Medicina, UANL.

### References

1. Alizadeh M, Kolecka A, Boekhout T, Zarrinfar H, Ghanbari Nahzag MA, Badiee P, et al. Identification of *Candida* species isolated from vulvovaginitis using matrix assisted laser desorption/ionization-time of flight mass spectrometry. *Curr Med Mycol*. 2017;3(4):21-5. doi: 10.29252/cmm.3.4.21. [PubMed: 29707675]. [PubMed Central: PMC5917097].
2. Esmailzadeh A, Zarrinfar H, Fata A, Sen T. High prevalence of candiduria due to non-albicans *Candida* species among diabetic patients: A matter of concern? *J Clin Lab Anal*. 2018;32(4): e22343. doi: 10.1002/jcla.22343. [PubMed: 29076587].
3. Zarrinfar H, Kaboli S, Dolatabadi S, Mohammadi R. Rapid detection of *Candida* species in bronchoalveolar lavage fluid from patients with pulmonary symptoms. *Braz J Microbiol*. 2016;47(1):172-6. doi: 10.1016/j.bjm.2015.02.001. [PubMed: 26887241]. [PubMed Central: PMC4822774].
4. Pfaller MA, Andes DR, Diekema DJ, Horn DL, Reboli AC, Rotstein C, et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of *Candida* in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. *PLoS One*. 2014;9(7): e101510. doi: 10.1371/journal.pone.0101510. [PubMed: 24991967]. [PubMed Central: PMC4081561].
5. Correia A, Sampaio P, James S, Pais C. *Candida bracarensis* sp. nov., a novel anamorphic yeast species phenotypically similar to *Candida glabrata*. *Int J Syst Evol Microbiol*. 2006;56(Pt 1):313-7. doi: 10.1099/jis.0.64076-0. [PubMed: 16403904].
6. Alcoba-Florez J, Mendez-Alvarez S, Cano J, Guarro J, Perez-Roth E, del Pilar Arevalo M. Phenotypic and molecular characterization of *Candida nivariensis* sp. nov., a possible new opportunistic fungus. *J Clin Microbiol*. 2005;43(8):4107-11. doi: 10.1128/JCM.43.8.4107-4111.2005. [PubMed: 16081957]. [PubMed Central: PMC1233986].
7. Haynes K. Virulence in *Candida* species. *Trends Microbiol*. 2001;9(12):591-6. [PubMed: 11728872].
8. Angoulvant A, Guitard J, Hennequin C. Old and new pathogenic *Nakaseomyces* species: Epidemiology, biology, identification, pathogenicity and antifungal resistance. *FEMS Yeast Res*. 2016;16(2):fov114. doi: 10.1093/femsyr/fov114. [PubMed: 26691882].
9. Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. *Nat Rev Dis Primers*. 2018;4:18026. doi: 10.1038/nrdp.2018.26. [PubMed: 29749387].
10. Bizerra FC, Jimenez-Ortigosa C, Souza AC, Breda GL, Queiroz-Telles F, Perlin DS, et al. Breakthrough candidemia due to multidrug-resistant *Candida glabrata* during prophylaxis with a low dose of micafungin. *Antimicrob Agents Chemother*. 2014;58(4):2438-40. doi: 10.1128/AAC.02189-13. [PubMed: 24468776]. [PubMed Central: PMC4023795].
11. Green MR, Sambrook J. Isolation of high-molecular-weight DNA using organic solvents. *Cold Spring Harb Protoc*. 2017;2017(4):pdb prot093450. doi: 10.1101/pdb.prot093450. [PubMed: 28373491].
12. White TJ, Bruns T, Lee S, Taylor J. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, editors. *PCR protocols*. San Diego: Academic Press; 1990. p. 315-22. doi: 10.1016/b978-0-12-372180-8.50042-1.



13. Chakrabarti A, Nayak N, Talwar P. In vitro proteinase production by *Candida* species. *Mycopathologia*. 1991;**114**(3):163–8. [PubMed: [1886642](#)].
14. Price MF, Wilkinson ID, Gentry LO. Plate method for detection of phospholipase activity in *Candida albicans*. *Sabouraudia*. 1982;**20**(1):7–14. [PubMed: [7038928](#)].
15. Slifkin M. Tween 80 opacity test responses of various *Candida* species. *J Clin Microbiol*. 2000;**38**(12):4626–8. [PubMed: [11101607](#)]. [PubMed Central: [PMC87648](#)].
16. Luo G, Samaranayake LP, Yau JY. *Candida* species exhibit differential in vitro hemolytic activities. *J Clin Microbiol*. 2001;**39**(8):2971–4. doi: [10.1128/JCM.39.8.2971-2974.2001](#). [PubMed: [11474025](#)]. [PubMed Central: [PMC88272](#)].
17. Koga-Ito CY, Lyon JP, Vidotto V, de Resende MA. Virulence factors and antifungal susceptibility of *Candida albicans* isolates from oral candidosis patients and control individuals. *Mycopathologia*. 2006;**161**(4):219–23. doi: [10.1007/s11046-005-0001-x](#). [PubMed: [16552484](#)].
18. Treviño-Rangel RJ, Espinosa-Perez JF, Villanueva-Lozano H, Montoya AM, Andrade A, Bonifaz A, et al. First report of *Candida bracarensis* in Mexico: Hydrolytic enzymes and antifungal susceptibility pattern. *Folia Microbiol (Praha)*. 2018;**63**(4):517–23. doi: [10.1007/s12223-018-0592-5](#). [PubMed: [29488180](#)].
19. Rex JH. *Reference method for broth dilution antifungal susceptibility testing of yeasts*. 4th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
20. Aktas E, Yigit N, Ayyildiz A. Esterase activity in various *Candida* species. *J Int Med Res*. 2002;**30**(3):322–4. doi: [10.1177/147323000203000315](#). [PubMed: [12166351](#)].
21. Kantarcioglu AS, Yucel A. Phospholipase and protease activities in clinical *Candida* isolates with reference to the sources of strains. *Mycoses*. 2002;**45**(5-6):160–5. [PubMed: [12100532](#)].
22. Rodrigues AG, Pina-Vaz C, Costa-de-Oliveira S, Tavares C. Expression of plasma coagulase among pathogenic *Candida* species. *J Clin Microbiol*. 2003;**41**(12):5792–3. doi: [10.1128/jcm.41.12.5792-5793.2003](#). [PubMed: [14662985](#)]. [PubMed Central: [PMC308979](#)].
23. Gokce G, Cerikcioglu N, Yagci A. Acid proteinase, phospholipase, and biofilm production of *Candida* species isolated from blood cultures. *Mycopathologia*. 2007;**164**(6):265–9. doi: [10.1007/s11046-007-9053-4](#). [PubMed: [17874282](#)].
24. Oksuz S, Sahin I, Yildirim M, Gulcan A, Yavuz T, Kaya D, et al. Phospholipase and proteinase activities in different *Candida* species isolated from anatomically distinct sites of healthy adults. *Jpn J Infect Dis*. 2007;**60**(5):280–3. [PubMed: [17881867](#)].
25. Yigit N, Aktas AE, Ayyildiz A. Detection of coagulase activity in pathogenic *Candida* species. *J Int Med Res*. 2008;**36**(6):1378–82. doi: [10.1177/147323000803600627](#). [PubMed: [19094449](#)].
26. D'Eca Junior A, Silva AF, Rosa FC, Monteiro SG, de Maria Silva Figueiredo P, de Andrade Monteiro C. In vitro differential activity of phospholipases and acid proteinases of clinical isolates of *Candida*. *Rev Soc Bras Med Trop*. 2011;**44**(3):334–8. [PubMed: [21901875](#)].
27. Chin VK, Foong KJ, Maha A, Rusliza B, Norhafizah M, Ng KP, et al. *Candida albicans* isolates from a Malaysian hospital exhibit more potent phospholipase and haemolysin activities than non-*albicans* *Candida* isolates. *Trop Biomed*. 2013;**30**(4):654–62. [PubMed: [24522136](#)].
28. Tellapragada C, Eshwara VK, Johar R, Shaw T, Malik N, Bhat PV, et al. Antifungal susceptibility patterns, in vitro production of virulence factors, and evaluation of diagnostic modalities for the speciation of pathogenic *Candida* from blood stream infections and vulvovaginal candidiasis. *J Pathog*. 2014;**2014**:142864. doi: [10.1155/2014/142864](#). [PubMed: [25110589](#)]. [PubMed Central: [PMC4119684](#)].
29. Deorukhkar SC, Saini S, Mathew S. Non-*albicans* *Candida* infection: An emerging threat. *Interdiscip Perspect Infect Dis*. 2014;**2014**:615958. doi: [10.1155/2014/615958](#). [PubMed: [25404942](#)]. [PubMed Central: [PMC4227454](#)].
30. Mutlu Sariguzel F, Berk E, Koc AN, Sav H, Demir G. Investigation of the relationship between virulence factors and genotype of *Candida* spp. isolated from blood cultures. *J Infect Dev Ctries*. 2015;**9**(8):857–64. doi: [10.3855/jidc.5359](#). [PubMed: [26322878](#)].
31. Atalay MA, Koc AN, Demir G, Sav H. Investigation of possible virulence factors in *Candida* strains isolated from blood cultures. *Niger J Clin Pract*. 2015;**18**(1):52–5. doi: [10.4103/1119-3077.146979](#). [PubMed: [2551344](#)].
32. Riceto EB, Menezes Rde P, Penatti MP, Pedroso Rdos S. Enzymatic and hemolytic activity in different *Candida* species. *Rev Iberoam Micol*. 2015;**32**(2):79–82. doi: [10.1016/j.riam.2013.11.003](#). [PubMed: [24704439](#)].
33. Figueiredo-Carvalho MHG, Ramos LS, Barbedo LS, de Oliveira JCA, Dos Santos ALS, Almeida-Paes R, et al. Relationship between the antifungal susceptibility profile and the production of virulence-related hydrolytic enzymes in Brazilian clinical strains of *Candida glabrata*. *Mediators Inflamm*. 2017;**2017**:8952878. doi: [10.1155/2017/8952878](#). [PubMed: [28814823](#)]. [PubMed Central: [PMC5549490](#)].
34. Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J. *Candida glabrata*, *Candida parapsilosis* and *Candida tropicalis*: biology, epidemiology, pathogenicity and antifungal resistance. *FEMS Microbiol Rev*. 2012;**36**(2):288–305. doi: [10.1111/j.1574-6976.2011.00278.x](#). [PubMed: [21569057](#)].
35. Sardi JC, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJ. *Candida* species: Current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. *J Med Microbiol*. 2013;**62**(Pt 1):10–24. doi: [10.1099/jmm.0.045054-0](#). [PubMed: [23180477](#)].
36. Pakshir K, Zomorodian K, Karamitalab M, Jafari M, Taraz H, Ebrahimi H. Phospholipase, esterase and hemolytic activities of *Candida* spp. isolated from onychomycosis and oral lichen planus lesions. *J Mycol Med*. 2013;**23**(2):113–8. doi: [10.1016/j.mycmed.2013.04.007](#). [PubMed: [23706304](#)].
37. Luo G, Samaranayake LP, Cheung BP, Tang G. Reverse transcriptase polymerase chain reaction (RT-PCR) detection of HLP gene expression in *Candida glabrata* and its possible role in in vitro haemolysin production. *APMIS*. 2004;**112**(4-5):283–90. doi: [10.1111/j.1600-0463.2004.apm11204-0509.x](#). [PubMed: [15233644](#)].
38. Srivastava VK, Suneetha KJ, Kaur R. A systematic analysis reveals an essential role for high-affinity iron uptake system, haemolysin and CFEM domain-containing protein in iron homeostasis and virulence in *Candida glabrata*. *Biochem J*. 2014;**463**(1):103–14. doi: [10.1042/BJ20140598](#). [PubMed: [24987864](#)].
39. Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, et al. Increasing echinocandin resistance in *Candida glabrata*: Clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. *Clin Infect Dis*. 2013;**56**(12):1724–32. doi: [10.1093/cid/cit136](#). [PubMed: [23487382](#)]. [PubMed Central: [PMC3658363](#)].
40. Morales-Lopez S, Dudiuk C, Vivot W, Szusz W, Cordoba SB, Garcia-Effron G. Phenotypic and molecular evaluation of echinocandin susceptibility of *Candida glabrata*, *Candida bracarensis*, and *Candida nivariensis* strains isolated during 30 years in Argentina. *Antimicrob Agents Chemother*. 2017;**61**(7). doi: [10.1128/AAC.00170-17](#). [PubMed: [28461313](#)]. [PubMed Central: [PMC5487631](#)].